A Phase 1 Study Evaluating the Safety and Pharmacokinetics of Venetoclax in Japanese Subjects With Hematological Malignancies

Trial Profile

A Phase 1 Study Evaluating the Safety and Pharmacokinetics of Venetoclax in Japanese Subjects With Hematological Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Jun 2017

At a glance

  • Drugs Venetoclax (Primary)
  • Indications Chronic lymphocytic leukaemia; Multiple myeloma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors AbbVie
  • Most Recent Events

    • 25 Jun 2017 Results (n=20) presented at the 22nd Congress of the European Haematology Association
    • 17 Apr 2017 Planned End Date changed from 1 Nov 2018 to 6 Feb 2020.
    • 17 Jan 2017 Planned number of patients changed from 30 to 36.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top